fluconazole has been researched along with Granulocytic Leukemia, Chronic in 5 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models." | 6.67 | Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994) |
| "Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models." | 2.67 | Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turgut, B | 1 |
| Vural, O | 1 |
| Demir, M | 1 |
| Kaldir, M | 1 |
| Bodey, GP | 1 |
| Anaissie, EJ | 1 |
| Elting, LS | 1 |
| Estey, E | 1 |
| O'Brien, S | 1 |
| Kantarjian, H | 1 |
| Epstein, JB | 1 |
| Ransier, A | 1 |
| Lunn, R | 1 |
| Chin, E | 1 |
| Jacobson, JJ | 1 |
| Le, N | 1 |
| Reece, D | 1 |
| Takahashi, N | 1 |
| Maruta, A | 1 |
| Hashimoto, C | 1 |
| Kato, K | 1 |
| Tanabe, J | 1 |
| Kodama, F | 1 |
| Oba, R | 1 |
| Harada, H | 1 |
| Omine, M | 1 |
| Jakab, K | 1 |
| Kelemen, E | 1 |
| Váradi, G | 1 |
| Török, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
1 trial available for fluconazole and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Blast Crisis; Female; Flu | 1994 |
4 other studies available for fluconazole and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B.
Topics: Amphotericin B; Arthritis, Infectious; Blast Crisis; Candidiasis; Drug Combinations; Drug Resistance | 2002 |
Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Bone Marrow Transplantation; Candidiasis, Oral; Dental C | 1996 |
[Successful allogeneic bone marrow transplantation following fungal liver abscess treatment in a patient with chronic myeloid leukemia in blastic crisis].
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Cris | 2000 |
[Amphotericin B resistant severe hepato-splenic candidiasis, responding to fluconazole, in a patient following bone marrow transplantation].
Topics: Adult; Amphotericin B; Bone Marrow Transplantation; Candidiasis; Female; Fluconazole; Humans; Leukem | 1991 |